Pfizer announces results from XELJANZ XR ORAL Shift study

This article was originally published here

Patients who achieved low disease activity (LDA) with XELJANZ (tofacitinib) extended release (XR) 11 mg once daily (QD) plus methotrexate (MTX) after a 24-week open-label run-in period, were

The post Pfizer announces results from XELJANZ XR ORAL Shift study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply